These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

803 related items for PubMed ID: 23256501

  • 21. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
    Dube A, Singh N, Sundar S, Singh N.
    Parasitol Res; 2005 Jun; 96(4):216-23. PubMed ID: 15868188
    [Abstract] [Full Text] [Related]

  • 22. Comment on: leishmaniasis: an update of current pharmacotherapy.
    Arya SC, Agarwal N.
    Expert Opin Pharmacother; 2013 Jun; 14(9):1275-6. PubMed ID: 23621855
    [No Abstract] [Full Text] [Related]

  • 23. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS, Kumar A, Hossain AFMA, Mahshin M, Sharma A, Hossain MA, Sharma V, Haque R, Shamsuzzaman AKM, Maruf S, Ghosh P, Ahuja V, Mondal D.
    Infect Dis Poverty; 2018 Aug 13; 7(1):80. PubMed ID: 30099967
    [Abstract] [Full Text] [Related]

  • 24. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
    Das VN, Ranjan A, Bimal S, Siddique NA, Pandey K, Kumar N, Verma N, Singh VP, Sinha PK, Bhattacharya SK.
    Natl Med J India; 2005 Aug 13; 18(3):131-3. PubMed ID: 16130613
    [Abstract] [Full Text] [Related]

  • 25. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
    Oliva G, Foglia Manzillo V, Pagano A.
    Parassitologia; 2004 Jun 13; 46(1-2):231-4. PubMed ID: 15305724
    [Abstract] [Full Text] [Related]

  • 26. Recent advances in the treatment of visceral leishmaniasis.
    Davidson RN, Croft SL.
    Trans R Soc Trop Med Hyg; 1993 Jun 13; 87(2):130-1, 141. PubMed ID: 8393221
    [No Abstract] [Full Text] [Related]

  • 27. Evaluating drug resistance in visceral leishmaniasis: the challenges.
    Hendrickx S, Guerin PJ, Caljon G, Croft SL, Maes L.
    Parasitology; 2018 Apr 13; 145(4):453-463. PubMed ID: 27866478
    [Abstract] [Full Text] [Related]

  • 28. Current diagnosis and treatment of visceral leishmaniasis.
    Mondal S, Bhattacharya P, Ali N.
    Expert Rev Anti Infect Ther; 2010 Aug 13; 8(8):919-44. PubMed ID: 20695748
    [Abstract] [Full Text] [Related]

  • 29. Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches.
    Murray HW.
    Int J Infect Dis; 2000 Aug 13; 4(3):158-77. PubMed ID: 11179920
    [Abstract] [Full Text] [Related]

  • 30. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
    Rihl M, Stoll M, Ulbricht K, Bange FC, Schmidt RE.
    J Infect; 2006 Jul 13; 53(1):e25-7. PubMed ID: 16274744
    [Abstract] [Full Text] [Related]

  • 31. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
    Rosenthal E, Delaunay P, Jeandel PY, Haas H, Pomares-Estran C, Marty P.
    Med Mal Infect; 2009 Oct 13; 39(10):741-4. PubMed ID: 19783391
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Challenges in the management of visceral leishmaniasis.
    Sundar S, Kumar A.
    Indian Pediatr; 2005 Jun 13; 42(6):523-6. PubMed ID: 15995268
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
    Escobar P, Yardley V, Croft SL.
    Antimicrob Agents Chemother; 2001 Jun 13; 45(6):1872-5. PubMed ID: 11353640
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.